Oscillate (LON: MUSH) has entered into non-binding heads of terms for the acquisition of Quantum Hydrogen Inc. The bid target has exploration rights over 60,000 acres in the state of Minnesota. There is a 60-day due diligence period. Richard and Charlott Edwards have reduced their stake in Oscillate from 8.31% to 7.6%. The share price increased 36% to 0.85p. That is the highest level for nearly two years.
Quantum Exponential Group (LON: QBIT) is still talking to a potential investor and there have been indications of interest from others. These discussions have been going on for weeks, but management believes that they have potential for a positive conclusion. The share price is 11.1% higher at 0.5p.
Tap Global Group (LON: TAP) chief executive Arsen Torosian bought 12.25 million shares at 0.5p each. The share price improved 6.25% to 0.85p.
Software developer IntelliAM (LON: INT) has secured a funding award of £263,000 from DIF Lighthouse Fund. This is for research into the application of AI in lubrication analysis. A machine learning model will be created. Gresham House Asset Management holds 23.5% of the company. The share price rose 4% to 65p.
Shepherd Neame (LON: SHEP) non-executive director George Barnes bought 1,000 shares at 666p each. The share price moved up 1.13% to 672.5p.
FALLERS
Gunsynd (LON: GUN) has decided to leave Aquis and it plans to acquire a 100% stake in the Falcon Lake uranium, copper and cobalt project and the Bear-Twit VMS project in Canada. The consideration is £200,000 in shares and cash. It will also commit £100,000 to work programmes. The last day of dealings on Aquis will be 9 August. The share price dipped 3.7% to 0.13p.
Shortwave Life Sciences (LON: PSY) has received a positive response from the PCT examining authority acknowledging its patent claims for its drug delivery platform for psychedelic-based drugs. More than nine million shares have been issued as deferred consideration for the acquisition of Shortwave Pharma Inc. The share price fell 2.58% to 1.51p.
Skin treatments developer Incanthera (LON: INC) has received a second Skin + CELL production order of 250,000 units from Marionnaud AG. This will be delivered before the end of March 2025. Total projected revenues for both orders are more than £10m. The share price lost 1.75% to 28p, but it is still more than quadruple the level at the start of the year.